Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If pps is this low now,
what is going to happen when we see the bulk of those bad loan shares come to the market???
ACTC gives us a nice Christmas present
bag full of coal................
That dip was sharp today because it was design by the MM to trigger all the stop loss orders that he could. There are not many shares for sell, so the only way the MM can get shares is by this method. He can see the stop orders.
I had a stop loss order set yesterday, at what I thought was low enough to be somewhat safe. The MM drove the price down to it, but I closed the order just in time before it was triggered. As soon as I did that, the downward pressure stopped. I guess there were no more visible stop order.
Today I had a stop loss order set at @6.65. The price was driven down and the shares taken. I didn't cancel the order in time. Just look at 9:56am on the daily chart you can see that little spike down to take my shares. Then there was a temporary spike up, then I guess the MM saw more stop loss orders down around $6.50 and proceeded to drive the pps with those 100 share lots to take out 6.50. The low for the day.
That is the danger of using a stop loss on a fast trading stock. I seen this action many a times over the years.
So, is .104 the price until all those shares from the lawsuits get passed through and sold?
Is there an expected settlement date for these lawsuits.
Can any type of deal be done or good news released until this is settled?
Look like pps can't move until then.
Great CC
just wish I could buy some more shares AH
before it jumps up tomorrow!..
Can you say China!!!!!!
Just for the sake of guessing...
How about ABBOTT
They are spinning off into two companies soon: Pharma and medical supplies.
May be they need more stuff in their new Pharma company pipeline????
New to OCZ
Why am I here: Someone I know kept bragging about their SSD they bought and how fast it was. I just bought a new laptop with a SSD in it. My friend was right..it is very fast.. This friend mention OCZ a few weeks ago.. been following since and bought a few shares
Needless to say, even thought I am up a few cents, and I would like to buy some more, however this price action and the very large Short position is somewhat intimidating at the least.
For you long, can someone explain what caused(ing) this high short position??? I guess I need to dig a little deeper into the this past year news.
Here today, even with a great market OCZ is turning red?????
TIA
Is Hope still an option here anymore?
Getting wiped out
Is ACTC done for?
Thanks for the link
That sure was a depressing read.....
This pps action at the close truly sucks!
Has ACTC diluted that much between last month and today to cause such a fall?
Isn't there any good news out there?
Is the person who write these PR "stoned" when he writes them. They are so far out there with all these little comments like: "Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in." There is a long path to any FDA approval.
But I do hope this PR can do something to the Stockprice!
The trails for FDA purposes may take 2 years
but the results of each trail will be known along the way.
Either there is an improvement or Not!
They surely can't keep that secret.
ACT Receives Approval from Data and Safety Monitoring Board (DSMB) to Treat Next Patients in Stem Cell Clinical Trials
Last update: 9/28/2011 8:30:09 AM
Pioneering Stem Cell Studies for Treating Macular Degeneration Advance to Next Step
MARLBOROUGH, Mass., Sep 28, 2011 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the independent Data and Safety Monitoring Board (DSMB) overseeing the Company's two ongoing stem cell clinical trials in the United States authorized ACT to move forward with enrolling and treating the next set of patients in each of the trials. In July, surgeons led by Steven Schwartz, M.D., Ahmanson Professor of Ophthalmology at the David Geffen School of Medicine at UCLA and retina division chief at UCLA's Jules Stein Eye Institute treated the first patients in the Company's clinical trials for Stargardt's Macular Dystrophy (SMD) and Dry Age-Related Macular Degeneration (Dry AMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs). Each patient received an injection of 50,000 hESC-derived RPE cells in one of their eyes. Both the Dry AMD and SMD clinical trials are dose-escalation studies involving twelve patients in each, and are designed to evaluate the safety and tolerability of the injected RPE cells. The study design involves four cohorts of three patients each being treated at a predetermined dose of RPE cells, ranging from 50,000 to 200,000 cells. Based on the results of the first patient in each study, the DSMB authorized the Company to move forward with the next two patients in the studies. Each of these additional patients will also be treated with 50,000 RPE cells.
"The unanimous recommendation of the DSMB to proceed with the next four patients represents a significant milestone for our clinical programs. We hope that the positive trend in clinical results derived from treating the first patients with our RPE cells will continue," said Robert Lanza, M.D., chief scientific officer of ACT. "The DSMB approval is an important step towards confirming the safety of our cells. We hope that the treatment of the next patients will provide further evidence that our stem cell-derived RPE cells are a safe and effective treatment option for patients with a range of macular degenerative diseases such as Dry AMD and SMD."
Wonder why ACTC is down?
This is the lowest ACTC has been in 6 months
Why now???
We all hope for very Good News come Oct....
but, what "bad news" could there be come Oct?
I can only think of the obvious: infection, rejection, some weird mutation???
And if we did get bad news...where would the pps be?
Is this MORE dilution?
No wonder why the pps can't move up.
Summary of the Shares offered by the Selling Stockholders
The following is a summary of the shares being offered by the selling stockholders:
Common Stock offered by the selling stockholders
Up to 72,135,892 shares of Common Stock including 49,840,148 shares issuable upon exercise of warrants.
Common Stock outstanding prior to the offering
1,590,808,502 (1)
Common Stock to be outstanding after the offering
1,640,648,650 assuming the full exercise of the warrants the underlying shares of which are included in this prospectus.
Use of proceeds
We will not receive any proceeds from the sale of the Common Stock hereunder.
Oh well, this probably mean more dilution of shares to pay off this lawsuit! Look like ACTC is never going to move back up.
Did the stock rally forget about ACTC?
Why are we stuck at .16 again?
http://finance.yahoo.com/q/ta?t=my&s=IVAN&l=on&z=l&q=c&c=
Just look at the 10 year chart and decide where IVAN is going to go??
IVAN is a company with good dreams, but no results.
Hurry up and wait!
OK, now that ACTC is back to .18
Now what?
Already had to many Buying Opportunities
Need some real Selling Opportunities
Guess we can't expect any movement in pps anytime soon. Would be nice to hold in the .20's.
Finally..some movement up!
Thought we never get out of .19's
Hope next week is even better.
Well, just came back from a 23 day tour of Europe (Amsterdam, Florence, Rome, Venice, Paris and other cities in between) and I can tell you from what I saw all the women wearing, anything goes(tight, loose, trashy, expensive and all others) So, all this company has to do is find a niche market. The Chinese tourist were buying everything up and the American looked as fat as ever.
Did they release any photos of their product line yet? Haven't seen anything yet.
Which direction?
Bummer ACTC can't hold it gains.
Yep being in the right place at the right time seems to be be nice.
Don't know about OBJE yet.
http://finance.yahoo.com/q/hp?s=OBJE.OB+Historical+Prices
All the volume has come recently.
How much is this from the hype that got us (or at least me) here????
Just may have to buy a few hundred shares just to keep it in my streamers, plus give me a reason to look at those tight jeans some more
Can't believe it myself..
Hard to believe that it is back to the .17's
" company looked young and sexy"
Well, I am a dirty old man...
that why I clicked on that banner ad showing of OBJE showing me that sexy young girl telling me to invest in OBJE
After googling around, afterward looking for info, i ended up here, among other places.
I remember looking at Hot Topics (HOTT) when it was a young company and thought about buying some shares..didn't do it.
I remember looking at CROX shoes many years ago, thought about buying some shares, didn't do it.
So, just maybe I should think about OBJE???
Plus I see all theses hot babes out on the street and they seem to be buying those tight fitting jeans..oo la la.
OBJE is on my watchlist!
Only thing that worries me is that they have a 100mil shares authorized and have only issued 13mil. They have no production yet and this cost money. So, do they dilute the shares????
Well, they sure got screwed then
Why this fall again????
I'll admit it..I first bought in at $2
Hoping to get back there again one day
only this time with about 265K more shares!!
GLTA
Advanced Cell Technology Comments on Recent Trading
Last update: 3/9/2011 12:15:01 PM
Phase I/II Trials Proceeding as Scheduled; Company Knows of No Reason for Decline in Stock Price
MARLBOROUGH, Mass., Mar 09, 2011 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTC Bulletin Board: ACTC), a leader in the field of regenerative medicine, commented today on recent trading activity in its stock. The Company knows of no business, clinical or financial reason for the stock's recent significant decline. The two Phase I/II clinical trials that ACT received FDA clearance on for its RPE program, including a Phase 1/2 trial in patients with dry age-related macular degeneration, are proceeding as scheduled.
ACT plans to update investors on its clinical trial progress when it holds a conference call for the investment community later this month in conjunction with the filing of its Form 10-K with the Securities and Exchange Commission.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit .